Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemia.

Abstract:

:In chronic lymphocytic leukemia (CLL), strategies to overcome drug resistance due to p53 dysfunction are highly needed. Platinum-based compounds such as cisplatinum (CDDP) are active in fludarabine-refractory CLL through a largely unknown mechanism. We analyzed the mechanism of action of CDDP in the context of p53 dysfunctionality. In vitro treatment with CDDP did not induce death in quiescent CLL cells, but did induce apoptosis in CD40-ligand (and CpG) stimulated and proliferating cells, irrespective of p53 function. In the p53 dysfunctional prolymphocytic cell-line MEC1, CDDP treatment resulted in apoptosis, cell cycle arrest and ABL1-dependent expression of TAp73, CDKN1A, PUMA and BID. TAp73 RNA-interference decreased sensitivity to CDDP. Finally, both in vitro stimulated CLL cells and lymph node (LN) derived CLL cells showed increased TAp73 expression in comparison with quiescent peripheral blood derived cells. Activity of CDDP may therefore be mediated by TAp73, especially in the context of activation such as occurs in the LN microenvironment.

journal_name

Leuk Lymphoma

journal_title

Leukemia & lymphoma

authors

Tonino SH,Mulkens CE,van Laar J,Derks IA,Suo G,Croon-de Boer F,van Oers MH,Eldering E,Wang JY,Kater AP

doi

10.3109/10428194.2014.996751

subject

Has Abstract

pub_date

2015-01-01 00:00:00

pages

2439-47

issue

8

eissn

1042-8194

issn

1029-2403

journal_volume

56

pub_type

杂志文章
  • IRF-3 gene polymorphisms are associated with the susceptibility to and the survival in chronic lymphocytic leukemia and could also serve as an auxiliary index.

    abstract::The objective of this article was to investigate the relationship between IRF-3 gene polymorphisms and the susceptibility and prognosis of CLL. Between January 2011 and August 2012, 108 CLL patients and 112 healthy were enrolled in the study. DHPLC and Shesis software were applied in our study. In rs7251, CG genotype ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2016.1193858

    authors: Zhang ZX,Shen CF,Shou LH,Fang Q

    更新日期:2017-03-01 00:00:00

  • The late adverse events of rituximab therapy--rare but there!

    abstract::Rituximab, an anti CD20 monoclonal antibody, has now become a cornerstone in the treatment of many CD20 positive hematological malignancies and a variety of autoimmune disorders. In contrast to the acute allergic and cytokine associated reactions, late adverse events of rituximab are indeed uncommon but at the same ti...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428190902934944

    authors: Ram R,Ben-Bassat I,Shpilberg O,Polliack A,Raanani P

    更新日期:2009-07-01 00:00:00

  • Risk factors for the development of atrial fibrillation on ibrutinib treatment.

    abstract::Ibrutinib increases the risk of atrial fibrillation (AF), but the associated risk factors are not clearly defined. We performed retrospective review of ibrutinib-treated patients in a large academic practice to identify risk factors for new-onset AF. Variables with p-values <.05 in logrank analysis were included as pa...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2018.1533129

    authors: Lentz R,Feinglass J,Ma S,Akhter N

    更新日期:2019-06-01 00:00:00

  • Complex IgA gammopathy in Gaucher's disease.

    abstract::A 55-year-old Jewish patient was simultaneously diagnosed as having Gaucher's disease and IgA multiple myeloma. Serum protein electrophoresis and immunoelectrophoresis showed two different IgA kappa type monoclonal spikes. After four years of observation, a rapid fatal course of disease developed together with express...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199509054770

    authors: Shvidel L,Hurwitz N,Shtalrid M,Zur S,Oliver O,Berrebi A

    更新日期:1995-12-01 00:00:00

  • Human NK cells in health and disease: clinical, functional, phenotypic and DNA genotypic characteristics.

    abstract::Natural killer (NK) cells are the subject of great current interest because of their possible (in vivo) role in tumour cell surveillance and killing, and because of the potential application of cytokine-modulated NK cells in cancer immunotherapy. In addition, clonal proliferations of NK-associated (NKa) cell populatio...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199209049794

    authors: Richards SJ,Scott CS

    更新日期:1992-08-01 00:00:00

  • Initial therapy for acute myeloid leukemia in older patients: principles of care.

    abstract::Older patients with acute myeloid leukemia (AML) frequently have significant comorbidities, geriatric syndromes, and high-risk leukemia that make them susceptible to high early mortality, chemotherapy-related toxicities, and poor long-term survival. The receipt of chemotherapy or hematopoietic cell transplantation is ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/10428194.2017.1323275

    authors: Bhatt VR,Gundabolu K,Koll T,Maness LJ

    更新日期:2018-01-01 00:00:00

  • Isolated central nervous system relapse in aggressive non-Hodgkin's lymphoma: the Bologna experience.

    abstract::Isolated central nervous system (CNS) relapse was evaluated in terms of incidence, risk factors, and outcome in a consecutive cohort of 175 patients with aggressive non-Hodgkin's lymphoma in which no case of lymphoblastic or Burkitt's lymphoma was encountered. All these patients had obtained a complete remission with ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199909058415

    authors: Zinzani PL,Magagnoli M,Frezza G,Prologo G,Gherlinzoni F,Bendandi M,Albertini P,Babini L,D'Alessandro R,Tura S

    更新日期:1999-02-01 00:00:00

  • A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172).

    abstract::Bortezomib and gemcitabine have each shown activity as single agents in mantle cell lymphoma (MCL), which is incurable. The purpose of this phase II study was to determine the efficacy and safety of the previously unstudied combination of bortezomib and gemcitabine in patients with relapsed or refractory MCL. Patients...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究

    doi:10.3109/10428194.2010.546015

    authors: Kouroukis CT,Fernandez LA,Crump M,Gascoyne RD,Chua NS,Buckstein R,Turner R,Assouline S,Klasa RJ,Walsh W,Powers J,Eisenhauer E

    更新日期:2011-03-01 00:00:00

  • CD105 (endoglin) expression on hematopoietic stem/progenitor cells.

    abstract::Endoglin (CD105) is a component of the transforming growth factor-beta (TGF-beta) receptor (TGF-betaR) complex. Together with betaglycan, CD105 is considered as a TGF-betaR accessory molecule (also called TGF-betaRIII), but its functions in the receptor-ligand interactions are still poorly understood. A small subset o...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428190109097744

    authors: Pierelli L,Bonanno G,Rutella S,Marone M,Scambia G,Leone G

    更新日期:2001-11-01 00:00:00

  • Advances in umbilical cord blood transplant: a summary of the 11th International Cord Blood Symposium, San Francisco, 6-8 June 2013.

    abstract::The 11th International Cord Blood Symposium was devoted to advances in umbilical cord blood (UCB) research and transplant. Results of cord blood transplant (UCB SCT) for congenital storage disease and hemoglobinopathies are encouraging, but UCB SCT may also be useful for older adults with hematologic malignancies, and...

    journal_title:Leukemia & lymphoma

    pub_type:

    doi:10.3109/10428194.2013.837162

    authors: van Besien K

    更新日期:2014-08-01 00:00:00

  • Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics.

    abstract::Patients with chronic lymphocytic lymphoma (CLL) with high-risk cytogenetics [del(11q)(q22.3) or del(17p)(p13.1)] have limited therapeutic options and their prognosis remains poor. This analysis was conducted to determine the clinical activity of lenalidomide in patients with high-risk disease. Relapsed/refractory pat...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428190903406806

    authors: Sher T,Miller KC,Lawrence D,Whitworth A,Hernandez-Ilizaliturri F,Czuczman MS,Miller A,Lawrence W,Bilgrami SA,Sood R,Wood MT,Block AW,Lee K,Chanan-Khan AA

    更新日期:2010-01-01 00:00:00

  • Early mortality in children with acute lymphoblastic leukemia in a developing country: the role of malnutrition at diagnosis. A multicenter cohort MIGICCL study.

    abstract::The role of malnutrition at diagnosis as a predictor of early mortality in Mexican leukemia children remains controversial. The objective of present study was to investigate whether malnutrition was a predictor of early mortality during the first year of treatment in Mexican acute lymphoblastic leukemia (ALL) children...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,多中心研究

    doi:10.1080/10428194.2016.1219904

    authors: Martín-Trejo JA,Núñez-Enríquez JC,Fajardo-Gutiérrez A,Medina-Sansón A,Flores-Lujano J,Jiménez-Hernández E,Amador-Sanchez R,Peñaloza-Gonzalez JG,Alvarez-Rodriguez FJ,Bolea-Murga V,Espinosa-Elizondo RM,de Diego Flores-Chapa J,Pérez

    更新日期:2017-04-01 00:00:00

  • Successful treatment with Erwinia L-asparaginase for recurrent natural killer/T cell lymphoma.

    abstract::We describe a patient with natural killer (NK)/T cell lymphoma who relapsed after autologous peripheral blood stem cell transplantation (auto-PBSCT) and was successfully treated with Escherichia coli (E. coli) and Erwinia L-asparaginase. A 38-year-old male patient with ulcerated tumor at the left thigh was diagnosed a...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/1042819031000067873

    authors: Matsumoto Y,Nomura K,Kanda-Akano Y,Fujita Y,Nakao M,Ueda K,Horiike S,Yokota S,Kusuzaki K,Kitoh T,Watanabe A,Taniwaki M

    更新日期:2003-05-01 00:00:00

  • BRAF mutations in chronic lymphocytic leukemia.

    abstract::BRAF mutations have been shown to occur at a high frequency in melanoma and thyroid cancer, but also at lower frequencies in hematological malignancies. To assess the potential role of BRAF, we have sequenced exons 11 and 15 of BRAF in 138 cases with chronic lymphocytic leukemia (CLL) and 32 cases of B-cell prolymphoc...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2012.742525

    authors: Jebaraj BM,Kienle D,Bühler A,Winkler D,Döhner H,Stilgenbauer S,Zenz T

    更新日期:2013-06-01 00:00:00

  • Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplant.

    abstract::Infection, relapse, and GVHD can complicate allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although the effect of poor immune recovery on infection risk is well-established, there are limited data on the effect of immune reconstitution on relapse and survival, especially following T-cell depletion (TC...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2016.1265113

    authors: Goldberg JD,Zheng J,Ratan R,Small TN,Lai KC,Boulad F,Castro-Malaspina H,Giralt SA,Jakubowski AA,Kernan NA,O'Reilly RJ,Papadopoulos EB,Young JW,van den Brink MR,Heller G,Perales MA

    更新日期:2017-08-01 00:00:00

  • Clonality assays and megakaryocyte culture techniques in essential thrombocythemia.

    abstract::The development of techniques permitting in vitro growth of human megakaryocytes progenitors and more recently identification of the proto oncogene c-mpl (Mpl-R) and its ligand (Mpl-L) have created new opportunities for studying pathophysiology of E.T. Plasma or serum of E.T. patients was unable to overestimulate MK c...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199609074358

    authors: Yan L,Elkassar N,Gardin C,Briere J

    更新日期:1996-09-01 00:00:00

  • Molecular analysis of infant acute leukemia.

    abstract::Infant acute leukemia, known to have a poor outcome with conventional therapy, usually has a molecular rearrangement at chromosome band 11q23. The 11q23 translocation partner is typically at 4q21 in infant ALL, but other 11q23 translocation partners occur in infant ALL and AML. The MLL gene at 11q23, and the AF4 gene ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.3109/10428199709114159

    authors: Hilden JM,Frestedt JL,Kersey JH

    更新日期:1997-04-01 00:00:00

  • Graft-versus-host disease in mini-transplant.

    abstract::Mini-transplant has been used popularly in recent years. The intensity of conditioning regimens is less in mini-transplant, thus the anti-tumor effect is mainly carried by an immunological reaction, called graft-versus-leukemia (GVL)/graft-versus-tumor (GVT) effect. Thus, graft-versus-host disease (GVHD) in mini-trans...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,评审

    doi:10.1080/1042819042000219511

    authors: Mineishi S,Schuening FG

    更新日期:2004-10-01 00:00:00

  • Management of myelofibrosis after ruxolitinib failure.

    abstract::Over the last decade, the Janus kinase1/2 (JAK1/2) inhibitor ruxolitinib has emerged as a cornerstone of myelofibrosis (MF) management. Ruxolitinib improves splenomegaly and symptoms regardless of driver mutation status, and confers a survival advantage in patients with intermediate-2/high risk MF. However, cytopenias...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2020.1749606

    authors: Bose P,Verstovsek S

    更新日期:2020-08-01 00:00:00

  • Cigarette smoking is associated with a small increase in the incidence of non-Hodgkin lymphoma: a meta-analysis of 24 observational studies.

    abstract::Previous studies have evaluated the association between cigarette smoking and incidence of non-Hodgkin lymphoma (NHL) with inconclusive results. Our main objective was to evaluate this relationship using a meta-analysis of observational studies. A literature search was undertaken through October 2011 looking for perti...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章,meta分析

    doi:10.3109/10428194.2012.673225

    authors: Castillo JJ,Dalia S

    更新日期:2012-10-01 00:00:00

  • Acute promyelocytic leukemia in a HIV seropositive patient.

    abstract::Acute myeloid leukemia (AML) is infrequent in patients with human immunodeficiency virus (HIV) infection. Among AML, acute promyelocytic leukemia (APL) has been rarely described in such patients, with only one case being published. We report a 30 years-old intravenous drug abuser HIV-infected male with APL who attaine...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199709050899

    authors: Calvo R,Ribera JM,Battle M,Sancho JM,Granada I,Flores A,Millá F,Feliu E

    更新日期:1997-08-01 00:00:00

  • Splenic marginal zone lymphoma: a population-based study on the 2001-2008 incidence and survival in the United States.

    abstract::The epidemiology of splenic marginal zone lymphoma (SMZL) in the United States has not been addressed. Eight years of data (2001-2008) from 17 registries of the Surveillance, Epidemiology and End Results (SEER) program were used for this study. Of the 116,411 cases of non-Hodgkin lymphoma (NHL) in the registries, 763 ...

    journal_title:Leukemia & lymphoma

    pub_type: 历史文章,杂志文章

    doi:10.3109/10428194.2012.743655

    authors: Liu L,Wang H,Chen Y,Rustveld L,Liu G,Du XL

    更新日期:2013-07-01 00:00:00

  • Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing.

    abstract::Hematologic toxicity is reported as one of the most important problems connected with imatinib mesylate (IM) treatment in patients with chronic myelogenous leukemia (CML). Withholding the drug or application of growth factors is recommended in this situation. This study introduced a novel approach using intermittent d...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190600565057

    authors: Faber E,Nausová J,Jarosová M,Egorin MJ,Holzerová M,Rozmanová S,Maresová I,Divoký V,Indrák K

    更新日期:2006-06-01 00:00:00

  • Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts.

    abstract::The prognostic significance of rare BCR-ABL1 transcripts is uncertain in the tyrosine kinase inhibitor (TKI) era. In this retrospective study, 40 (1.7%) patients with rare BCR-ABL1 transcripts were identified from a cohort of 2331 chronic myeloid leukemia (CML) patients; 4 types of rare transcripts were identified, in...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2019.1607329

    authors: Xue M,Wang Q,Huo L,Wen L,Yang X,Wu Q,Pan J,Cen J,Ruan C,Wu D,Chen S

    更新日期:2019-12-01 00:00:00

  • Detection of proliferating cell nuclear antigen (PCNA) in peripheral blood mononuclear cells and sera of patients with malignant lymphoma.

    abstract::Proliferating cell nuclear antigen (PCNA) was detected in the peripheral blood mononuclear cells (PBMC) of patients with malignant lymphoma (ML). Twenty-one of 27 patients with ML had PCNA expressing PBMC (5.25+/-4.75% cells), which tended to increase in the advanced clinical stage of ML. PCNA in PBMC extracts was det...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199709058337

    authors: Takahashi T,Takasaki Y,Takeuchi K,Yamanaka K,Oshimi K,Hashimoto H

    更新日期:1997-12-01 00:00:00

  • Neurological presentation of Hodgkin lymphoma in the Italian Association of Pediatric Hematology and Oncology LH-2004 protocol.

    abstract::Neurological symptoms can represent the first clinical manifestation of central nervous system (CNS) involvement in Hodgkin lymphoma (HL). Because of its rarity, it is often misunderstood for other pathological processes. We report two cases of pediatric CNS HL, presenting with neurological symptoms at diagnosis. We h...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428194.2011.562573

    authors: Burnelli R,Fabbri E,Guerrini G,Sperlì D,D'ambrosio A

    更新日期:2011-06-01 00:00:00

  • A Novel Cell Line (NCU-L-1) from a Patient with Acute Lymphoblastic Leukemia, FAB, L3, Burkitt's Type.

    abstract::A novel cultured cell line, NCU-L-1, was established from a 71-year-old Japanese woman with acute lymphoblastic leukemia, L3 FAB, Burkitt's type. The NCU-L-1 cells were shown to have a mature B-cell phenotype on the basis of immunologic surface marker analysis; including IgG Lambda surface immunoglobulins, CD19, CD20 ...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.3109/10428199009050977

    authors: Nitta M,Iwaki O,Wakita A,Kodama H,Takeuchi G,Takada K,Mitomo Y,Yamamoto M,Amano M,Murate T,Koike K,Osada H,Ueda R,Shamoto M

    更新日期:1990-01-01 00:00:00

  • Induced apoptosis by mild hyperthermia occurs via telomerase inhibition on the three human myeloid leukemia cell lines: TF-1, K562, and HL-60.

    abstract::The purpose of this research was to understand the effect of hyperthermia on the telomerase activity in human leukemic cell lines (HL-60, K562, and TF-1). The cells were treated by hyperthermia at the range of 41-44 degrees C for 120 min and incubated for 96 h. Then telomerase activity, cell proliferation, and apoptos...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190903129130

    authors: Deezagi A,Manteghi S,Khosravani P,Vaseli-Hagh N,Soheili ZS

    更新日期:2009-09-01 00:00:00

  • Peripheral blood lymphocyte subsets of newly diagnosed DLBCL patients and their dynamic changes with rituximab based immunochemotherapy.

    abstract::The purpose of this study was to explore lymphocyte subsets of newly diagnosed DLBCL patients, and dynamics along with treatment of R-CHOP. A total of 40 DLBCL patients were enrolled. ALC of grade III-IV DLBCL patients was significantly lower than that of health controls (1.33*10E9/L vs 1.89*10E9/L, p = 0.003), mostly...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428194.2019.1617861

    authors: Yang Z,Yu W,Wang S,Zhou X,Liu S,Ma S

    更新日期:2019-12-01 00:00:00

  • Therapy-related acute lymphoblastic leukemia with MLL rearrangement following treatment of Burkitt's leukemia.

    abstract::The occurrence of therapy-related acute lymphoblastic leukemia (ALL) is rare and, to our knowledge, is not reported in patients treated for Burkitt's leukemia. We report on a child with ALL with translocation t(4;11)(q21;q23) involving the MLL gene, 13 months after chemotherapy for Burkitt's leukemia. This present obs...

    journal_title:Leukemia & lymphoma

    pub_type: 杂志文章

    doi:10.1080/10428190500052248

    authors: Millot F,Brizard F,Sorel N,Preudhomme C,Cividin M,Guilhot F,Brizard A

    更新日期:2005-06-01 00:00:00